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Abstract The secondquarter of2009saw steadyadvancesin
bone marrow biopsy (BMB) pathology. The following
publications are a personal selection of the highlights. Quality
issues in diagnostic immunohistochemistry for BMB have
largely been ignored in external quality assurance pro-
grammes, and this issue is highlighted. In other areas,
publications reflecting advances in flow cytometry and
aspirate morphology are discussed where translation to the
BMB is possible. Classifications undergo constant change,
and several publications address the redefinition of the cut off
points between malignancy, benign, and normal. Lastly,
current scientific research is presented where it is relevant to
the understanding of BMB pathobiology.
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Technical issues
With regard to immunohistochemistry (IHC), daily quality
control/quality assurance measures and participation in
external quality assurance (EQA) programmes are important
in ensuring good laboratory practise and patient care and are
standard practise in many subspecialties in histopathology
laboratories. Bone marrow biopsy (BMB) has been generally
excluded from EQA programmes for diagnostic IHC due to a
lack of standards for tissue processing. The European Bone
Marrow Working Group (EBMWG) has set up an EBMWG
IHC Committee with the task of exploring the plausibility of
an EQA programme for BMB IHC in Europe [1]. Twenty-
eight laboratories participated in a web-based anonymous
survey; 19 laboratories submitted a total of 109 slides
stained for CD34, CD117, CD20, CD3, Ki-67, and a
megakaryocyte marker of choice. Eight different fixatives
and nine different decalcification methods were used. Only
21% of laboratories did not have any poor results. The
CD117 and Ki-67 were the most problematic immunostains,
while CD20 was the least problematic.
The EBMWG IHC Committee calls for a reduction in
the tissue processing methods for BMB and establishment
of an EQA programme for BMB IHC to help diagnostic
IHC laboratories calibrate their tests according to expert
recommendations. This is especially necessary in the light
of recent introduction of IHC tests in BMB that may predict
therapeutic response [1].
Myelodysplastic and related syndromes
The International Working Group on Morphology of Myelo-
dysplastic Syndrome has attempted to establish morphological
definitions so that monocytes, including immature monocytes,
could be separated from the spectrum of monocyte precursors
[2]. Cells from peripheral blood or bone marrow were
selected to provide a large panel of normal and leukaemic
cells at different maturational stages and were submitted to
five experts who had previously reached a consensus on the
basis of microscopy in defining four subtypes:
1. Monoblast;
2. Promonocyte;
3. Immature monocyte; and
4. Mature monocyte.
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confirming that the criteria for defining the four subtypes
could be applied consistently. The monocyte is still the
most difficult cell to identify with confidence in the
peripheral blood or in the bone marrow in healthy
individuals, as well as in patients with infections and in
those with leukaemic proliferations, and this study estab-
lishes useful morphological criteria. It has now to be
established whether the monocyte subtypes thus defined
correlate with immunological or molecular markers and can
be translated into diagnostic categories in the BMB.
Ballmaier and Germeshausen have published a useful
review of congenital amegakaryocytic thrombocytopenia
(CAMT) [3], an extremely rare inherited bone marrow
failure syndrome, usually presenting as a severe thrombo-
cytopenia at birth due to ineffective megakaryocytopoiesis
and no characteristic physical anomalies. Usually, the
isolated thrombocytopenia progresses to pancytopenia
during the first years of life.
The BMB in CAMT at time of diagnosis is usually
normocellular with absent or severely reduced numbers of
megakaryocytes but normal development of other lineages.
Megakaryocytes are often small and immature. A few
CAMT patients have been reported with normal megakar-
yocyte numbers in initial bone marrow samples. The
progression to pancytopenia in most cases of CAMT is
associated with the development of a hypocellular marrow
and aplastic anaemia with a relative increase of lymphocytes.
Most of the cases of CAMT are caused by defective
expression or function of the thrombopoietin receptor due
to homozygous or compound heterozygous mutations in the
gene MPL. The essential roles of thrombopoietin as a
lineage specific regulator of platelet production and as a
regulator of haematopoietic stem cell function are reflected
in the haematological defects seen in affected individuals.
Myeloproliferative neoplasms (MPN)
Essential thrombocythaemia (ET) and primary myelofibro-
sis (PMF) overlap in clinical and pathological features but
differ in biological behaviour and prognosis. The latest
contributions to understanding the nature of these disorders
have focused on bone marrow microenvironment remodel-
ling and proliferative stress, recognising megakaryocytes
(MKCs) as "key-cells" [4]. Florena et al. [4] investigated
the apoptotic profile of ET and PMF MKCs in order to
further characterise the biology of these disorders. Bone
marrow biopsy from 30 patients with ET and 30 patients
with PMF were studied immunophenotypically for the
expression of pro-apoptotic (Fas, Fas-L, Bax, and Bad) and
anti-apoptotic (Bcl-2, Bcl-XL, and human telomerase
reverse transcriptase) molecules and the "executioner"
molecule caspase-3. The fraction of MKCs undergoing
apoptosis was assessed by deoxynucleotidyl transferase-
mediated dUTP nick-end labelling. Only the mitochondrial
pathway seemed to be involved in MKC apoptosis. The
anti-apoptotic molecule, Bcl-XL, was predominantly found
in ET MKCs while pro-apoptotic molecules, Bax and Bad,
showed a prevalent expression in PMF MKCs. A signifi-
cant fraction of PMF MKCs were committed to apoptosis
according to caspase-3 expression and TUNEL while only a
few ET cells were committed to apoptosis. hTERT was
significantly more expressed in PMF in agreement with the
proliferative nature of PMF [4]. The authors concluded that
ET and PMF MKCs, while morphologically similar, are
characterised by markedly different apoptotic profiles. The
higher apoptotic fraction of PMF was consistent with the
fibrotic nature of the disease, while the anti-apoptotic
profile of ET cells was compatible with a "steady"
maturative state [4].
The new World Health Organization (WHO) classifica-
tion of MPN has been revised to include the Janus Kinase 2
(JAK2) mutation status, lower threshold of platelet values
(450×10
9/L) in ET, and other advances in understanding
[5]. To investigate any change of incidence of MPN,
Girodon et al. [6] performed a retrospective study of a
population-based registry in the Côte d’Or area, France,
from 1980 to 2007. A total of 524 MPN were registered for
the 1980–2007 period, including 135 PV, 308 ET, and 81
PMF. No change in the incidence of either PVor PMF was
observed for the 2005–2007 period using the WHO 2008
criteria compared to 1980–2004. On the contrary, a
pronounced increase in the incidence of ET was noted after
2005, mainly due to the use of JAK2 mutation screening
and the lower platelet count threshold. The authors
concluded that their study confirms the relevance of the
new WHO diagnostic criteria particularly in allowing
earlier diagnosis of ET.
Splanchnicveinthrombosis(SVT)isaseverecomplication
of ET. No clear explanation has been given for the occurrence
of thrombosis in this unusual site in patients with ET, but the
existence of a specific association between unexplained SVT
and the JAK2 mutation has been reported [7]. Allegra et al.
[7] described SVT (portal and splenic vein) in a young
woman as the first presenting symptom. Extensive screening
for thrombophilia was negative. The patient did not fulfil the
WHO diagnostic criteria for MPN and the initial platelet
count was 310×10
9/l. Bone marrow biopsy, however,
showed a prominent increase of large megakaryocytes. The
reticulin pattern was normal. The diagnosis of ET was
established and supported by the presence of JAK2 V617F
mutation. After discharge, the number of platelets increased
gradually to 610×10
9/l. The authors concluded that in
patients with SVT, the detection of JAK2 V617F mutation
is diagnostic for masked MPN as could be documented by
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even when the platelet count is below the WHO threshold.
In addition to the JAK2 mutation, the thrombopoietin
receptor gene (MPL) mutation is a useful diagnostic marker
in MPN. The MPL is expressed in megakaryocytes and
exhibits the gain of function point mutation W515K/L in
approximately 5% of patients with PMF, representing one
subtype of MPN. Hussein et al [8] studied a series of
primary and secondary acute myeloid leukaemias (AML)
with megakaryoblastic phenotype and myelofibrosis unre-
lated to PMF which were analysed for the MPL W515K/L
mutation by pyrosequencing. In three of 12 cases (25%),
MPL W515L was found and in two of these a combination
with trisomy 21 or the Philadelphia chromosome occurred.
None of the four secondary AML cases evolving from pre-
existing PMF showed MPL W515K/L. The authors
concluded that MPL W515L occurs in a considerable
proportion of acute megakaryoblastic leukaemias with
myelofibrosis unrelated to PMF. As is the case of the
JAK2 mutation, MPL W515L is not specific for particular
types of MPN.
Data on angiogenesis in the bone marrow of BCR-ABL1-
negative MPN patients suggest an increase of the microvessel
density (MVD) and vascular endothelial growth factor
(VEGF) expression, but the relationship to the JAK2-V617F
status remains controversial [9]. Medinger et al. [9]
performed immunohistochemical studies of MVD and
VEGF expression in 100 MPN, including 24 ET, 46 PV,
26 PMF, 4 MDS/MPN, and 20 control reactive bone marrow
cases, and correlated these findings with biological and
clinical data and the JAK2-V617F status. A significantly
increased MVD was found, particularly that assessed by
CD105 and VEGF expression in MPN compared to controls
(PMF>PV>MDS/MPN>ET). Stronger association was ob-
served between CD105-MVD and VEGF expression, fibro-
sis, and JAK2 V617F mutant allele burden compared to
CD34-MVD. Microvessel density was strongly increased in
MPN with high JAK2 V617F mutant allele burden. The
authors concluded that the study highlighted the importance
of newly formed CD105+ vessels in the bone marrow of
MPN patients and indicates that assessment of CD105-MVD
better reflects angiogenic activity in MPN.
Systemic mastocytosis (SM) is a stem cell disorder
characterised histologically by the presence of multifocal
compact aggregates of mast cells in at least one extracuta-
neous organ with or without evidence of skin lesions. The
mast cell aggregates are accompanied by fibrosis, which is
often prominent, but is nevertheless, poorly understood.
Chiu et al. [10] evaluated the composition of the fibrotic
mast cell aggregates by studying eight BMB and two
spleens involved by SM and compared the findings with
those observed in other fibrotic bone marrow disorders,
such as PMF and metastatic malignancy (MM). It was
found that all cases showed marked reticulin and collagen
fibrosis. However, unlike PMF and MM, which are usually
associated with increased low-affinity nerve growth factor
receptor positivity, its expression was low in all cases of
systemic mastocytosis. Myofibroblastic differentiation was
only focally detected in two of eight bone marrow biopsies.
In all cases, the systemic mastocytosis lesions were largely
devoid of type IV collagen and laminin. The latter findings
were in contrast with those seen in cases of PMF and MM
where smooth muscle actin, collagen IV, and laminin were
expressed in most cases. In contrast with the other two
conditions, only minimal vascularity was detectable within
the fibrotic mast cell lesions. The authors concluded that
systemic mastocytosis exhibits a distinct pattern of stromal
change and suggested that the fibrogenetic mechanism in
systemic mastocytosis is most likely different from that of
other bone marrow neoplasms, which are also associated
with fibrosis. [10]
Clinical phenotype in SM is markedly variable, compli-
cating prognostication and therapeutic decision making.
The WHO classification recognises indolent (ISM), and
aggressive (ASM), SM with associated clonal haematologic
non-mast cell lineage disease (SM-AHNMD), and mast cell
leukaemia (MCL) as major categories [11]. In a retrospec-
tive study of 342 consecutive adult patients with SM seen at
the Mayo Clinic between 1976 and 2007, Lim et al. [12]
classified the cases according to the WHO as ISM in 46%,
SM-AHNMD in 40%, ASM in 12%, and MCL in 1%.
KITD816V was detected in bone marrow-derived DNA by
allele-specific polymerase chain reaction in 68% of 165
patients evaluated (ISM, 78%; ASM, 82%; and SM-
AHNMD, 60%); JAK2 V617F was detected in 4%, all in
SM-AHNMD. The life expectancy in ISM was not
significantly different from that of the age- and sex-
matched US population. In addition to non-ISM classifica-
tion, multivariable analysis identified advanced age, weight
loss, anaemia, thrombocytopenia, hypoalbuminaemia, and
excess bone marrow blasts as independent adverse prog-
nostic factors for survival. The authors concluded that their
study validates the prognostic relevance of the WHO
subclassification of SM and provides additional information
of value in terms of both risk stratification and interpreta-
tion of clinical presentation and laboratory results.
Chronic basophilic leukaemia (CBL) is a rare and poorly
characterised entity that was not listed as a diagnostic entity
in the 2008 WHO classification of tumours of haemato-
poietic and lymphoid tissues [13] and must as a result be
classified as an MPN, unclassifiable. Few cases have been
described in detail. Tang et al. [14] reported a patient who
presented with fatigue, weight loss, leukocytosis, persistent
prominent basophilia, and mild eosinophilia. The bone
marrow showed features characteristic of a myeloprolifer-
ative neoplasm with a marked increase in maturing
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tion, abnormal granulation, and abnormally low CD38
expression. Conventional karyotyping revealed t(5;12)(q31;
p13). ETV6, but not PDGFRB rearrangement, was detected
by fluorescence in situ hybridization. The authors conclude
that CBL is a very rare form of MPN but that increased
recognition, as well as additional molecular/genetic studies
might permit better classification of CBL, which does
appear to have distinct clinicopathologic features that
distinguish it from other unclassifiable MPNs.
Lymphoid lesions in the bone marrow
Monoclonal B cell lymphocytosis (MBL) is an asymptom-
atic monoclonal expansion of circulating chronic lympho-
cytic leukaemia (CLL)-phenotype B cells which, since the
publication of the International Workshop on CLL
(IWCLL) guideline in 2008 [15] has been defined as of
<5·0×10
9/l circulating B cells in the peripheral blood rather
than the absolute lymphocyte count. The relationship
between the newly defined MBL and Rai 0 CLL and the
impact of biological risk factors on MBL prognosis are
unknown. Rossi et al. [16] examined 460 B cell expansions
with CLL-phenotype. One hundred twenty-three clinical
MBL (cMBL) were compared to 154 Rai 0 CLL according
to clinical and biological profile and outcome. Clinical
MBL had better humoral immune capacity and lower
infection risk, lower prevalence of del11q22-q23/del17p13
and TP53 mutations, slower lymphocyte doubling time, and
longer treatment-free survival. Despite these favourable
features, all cMBL were projected to progress, and
lymphocytes <1·2×10
9/l and >3·7×10
9/l were the best
thresholds predicting the lowest and highest risk of
progression to CLL. Multivariate analysis identified the
presence of +12 or del17p13 as the sole independent
predictor of treatment requirement in cMBL. The authors
concluded that the newly defined cMBL has a more
favourable clinical course than Rai 0 CLL and may
influence management [16]. The revised criteria are likely
to affect the diagnosis of CLL-phenotype infiltrates in the
BMB, and haematopathologists should be aware of the new
criteria when diagnosing low level infiltrates.
The IGHV mutational status and ZAP-70 or CD38
expression have been shown to correlate with the clinical
course in CLL. The three markers may be discordant, and
there is as yet no consensus on their combined use in clinical
practise. Morabito et al. [17] studied 262 Binet stage A
patients for the three markers. Sixty patients were profiled
with HG-U133A gene expression chips. Disease progres-
sion was determined by time from diagnosis to treatment
(TTT). The probability of being treatment-free at 3 years
was significantly shorter in patients with un-mutated IGHV
genes, ZAP-70 positive, or CD38-positive cells All three
markers had an independent predictive value for TTT of
similar power. A prognostic system based on presence of
none (low-risk), 56%; one (intermediate-risk), 23%; or two
or three (high-risk) markers, 21% was generated with a
significant different clinical outcome. Specific transcrip-
tional patterns were significantly associated with risk
groups. Both ZAP-70 and CD38 should, therefore, be a
routine part of assessment of the BMB in CLL.
Familial clustering of the precursor condition monoclo-
nal gammopathy of undetermined significance (MGUS) has
previously been reported in case reports and in small
studies. Using population-based data from Sweden, Landg-
ren et al. [18] identified 4,458 MGUS patients, 17,505
population-based controls, and 14,621 first-degree relatives
of patients and 58,387 controls. Compared with relatives of
controls, relatives of MGUS patients had increased risk of
MGUS (2.8) multiple myeloma (MM, 2.9); lymphoplasma-
cytic lymphoma (LPL)/Waldenström macroglobulinemia
(WM, 4.0); and chronic lymphocytic leukaemia (2.0).
Relatives of patients with IgG/IgA MGUS had a 4.0-fold,
2.9-fold, and 20-fold elevated risk of developing MGUS,
MM, and LPL/WM, respectively. Relatives of IgM MGUS
patients had 5.0-fold increased CLL risk and non-
significant excess MM and LPL/WM risks. The results
were very similar when assessed by type of first-degree
relative, age at MGUS (above/below 65 years), or sex. Risk
of non-Hodgkin lymphoma or Hodgkin lymphoma was not
increased among MGUS relatives. Among first-degree
relatives of a nationwide MGUS cohort, we found elevated
risks of MGUS, MM, LPL/WM, and CLL. The authors
concluded that their findings support a role for germline
susceptibility genes, shared environmental influences, or an
interaction between both.
In a similar study, Vachon et al. [19] examined whether
MGUS is increased in first-degree relatives of MM
or MGUS patients. Probands were recruited from a
population-based prevalence study (MGUS) and the Mayo
Clinic (MM). By electrophoresis, MGUS was detected in
6% relatives, and immunofixation identified 28 additional
relatives for an age- and sex-adjusted prevalence of 8.1%.
The prevalence of MGUS in relatives increased with age.
Using similar MGUS detection methods, there was a
2.6-fold higher risk of MGUS in relatives compared with
the reference population. The increased risk was seen
among relatives of MM (2.0) and MGUS probands (3.3).
The authors concluded that the increased risk of MGUS in
first-degree relatives of MGUS or MM patients implies
shared environment and/or genetics.
Lymphoplasmacytic lymphoma is a low-grade B cell
malignancy exhibiting a cytological spectrum of plasma-
cytic differentiation ranging from small lymphocytes to true
plasma cells and, including cells with features intermediate
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cytes. Lymphoplasmacytic lymphoma characteristically has
an associated monoclonal serum immunoglobulin M (IgM)
paraprotein, although, it is indistinguishable from other
lymphoma types. In a subset of lymphoplasmacytic
lymphoma patients, the paraproteinemia is associated with
distinctive clinical findings such as serum hyperviscosity,
cryoglobulinemia, autoimmune phenomena such as periph-
eral neuropathy, and amyloidosis termed Waldenström's
macroglobulinemia. As lymphoplasmacytic lymphoma in-
frequently involves the lymph nodes or other extramedul-
lary sites, bone marrow biopsy is often the first and only
diagnostic tissue obtained, but the diagnosis is often
difficult and the presence of Waldenström's macroglobuli-
nemia unpredictable.
To address these issues, Morice et al. [20] studied
marrow histology, IHC, and flow cytometry from 35
lymphoplasmacytic lymphoma cases that had comprehen-
sive clinical assessment for Waldenström's macroglobuline-
mia. Both IHC and flow cytometry were useful in
identifying the lymphoid and plasmacytic disease compo-
nents. In 19 cases, IHC revealed an earlier unrecognised
pattern of plasma cell infiltration in which they were
physically separate from the lymphoid infiltrates. By
cytometry, approximately half of monotypic cells were
CD5 and/or CD23 positive, although, none had features of
chronic lymphocytic leukaemia. In 20 cases, the pattern of
cytoplasmic CD38 and CD138 co-expression detected by
cytometry was identical to that seen in plasma cell
malignancies such as multiple myeloma. However, in 18
of these 20 cases, these plasma cells were CD19 positive,
distinguishing them from those of true plasma cell neo-
plasms, which are CD19 negative. The two lymphoplasma-
cytic lymphoma cases with CD19-negative plasma cells
had an IgG isotype serum paraprotein. Apart from this, no
other pathological correlates of the clinical or laboratory
features of symptomatic Waldenström's macroglobulinemia
were identified [20].
Amyloid light chain amyloidosis (ALA) is a form of
plasma cell dyscrasia characterised by overproduction of
immunoglobulin light chains that form characteristic ab-
normally folded and aggregated insoluble fibrillar deposits
in various organs causing organ damage. Deshmukh et al.
[21] studied 36 well-documented cases of ALA. In all
cases, presence of amyloid deposits had been documented
by a congo red stain in the BMB and/or in other tissues.
Bone marrow biopsies showed varying degrees of plasma
cell (PC) infiltration. In eight cases with associated
myeloma, the mean percentage of PCs was 18%, while in
the remaining, it was 4%. Expression of CD20, CD79a,
CD56, cyclin D1, and EMA was noted in 42%, 86%, 50%,
53%, and 83% of cases, respectively. Aberrant antigen
expression in the form of CD56 and/or cyclin D1 expression
was seen in 79% of cases. Nine of 10 cases with small
lymphocyte-like PCs were positive for CD20, and all the 10
cases were positive for cyclin D1. Among cases lacking
small lymphocyte-like morphology, CD20 and cyclin D1
expression was seen in only six of 26 and eight of 26 cases,
respectively, CD20 expression correlated with cyclin D1
expression. Cytological atypia/pleomorphism was predictive
of associated myeloma. The authors concluded that BMB
involvement by neoplastic PCs in ALA can be identified by
their aberrant antigen expression apart from light chain
restriction.
CD123 is useful marker of plasmacytoid dendritic cells
and is expressed in these cells in chronic myelomonocytic
leukaemia and blastic plasmacytoid dendritic cell neo-
plasms amongst others. B lymphoid blasts from acute
lymphoblastic leukaemia (ALL) have been shown to
express functional CD123, and CD40 ligand stimulates
proliferation of precursor-B ALL by up-regulating CD123
expression. [22] However, the prevalence of CD123
expression in ALL is not clear. Djokic et al. [22] evaluated
CD123 expression in 95 paediatric and 24 adult ALL
patients and compared the results with the CD123 expres-
sion in normal B cell precursors. Early B cell precursors
were negative, while intermediate precursors and mature B
cells showed weak CD123 expression. Leukemic blasts in
31% of precursor-B ALL samples exhibited strong expres-
sion of CD123; 61% had moderate CD123 expression and
8% were negative; and 81.5% of ALL with hyperdiploid
karyotype (≥ 52 chromosomes) showed strong CD123
overexpression. In contrast, cases with ETV6/RUNX1
rearrangement had weak CD123 expression. The authors
concluded that overexpression of CD123 is an aberrant
phenotype present in a subset of precursor-B ALL with
hyperdiploid genotype and that it represents an additional
marker of good prognosis in paediatric precursor-B ALL.
Aberrant CD123 expression in ALL may, therefore, be a
good marker for monitoring of minimal residual disease.
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